The future of antibiotics lies in combination treatments

With the fast emergence of antimicrobial resistance, what is the future for antibiotic therapies? Find out more in this interview with Anthony Coates (Helperby Therapeutics; London, UK) from Future Drug Discovery.

Go to the profile of Future Drug Discovery
Apr 09, 2019

Antimicrobial resistance (AMR) is one of the greatest threats faced by modern medicine, with resistance of common bacteria at an epidemic level and the last of the penicillins being nearly obsolete in many countries, it is a key area of research in the field of drug discovery.

In a recent interview with Anthony Coates, Co-founder of the biopharmaceutical company Helperby Therapeutics (London, UK), we discuss the future for antibiotic therapies, why this is such an important field and how we could go about overcoming AMR.

Helperby works towards discovering and developing new antibiotic combinations, working alongside institutions to develop clinical trials and further pharmaceutical development. As well as being co-founder of the company, Coates is also a Professor of Medical Microbiology at St George's University (London, UK).

Read the full interview here.

Coates A. The future of antibiotics lies in combination treatments. Future Drug Discovery. (2019) 

Go to the profile of Future Drug Discovery

Future Drug Discovery

Journal , Future Science Group

Future Drug Discovery is a peer-reviewed journal covering the latest breakthrough science in drug discovery, research & development. The journal strives to drive drug discovery by taking a multi-disciplinary and forward-looking stance, presenting new advances and discussing their applications and translation. Future Drug Discovery will also be a forum for discussing the field at large.

No comments yet.